Newsmakers

ASM Microbe 2019 Conference Grants Both Poster and Oral Presentations to CytoDyn (OTC: CYDY) for its Pivotal Study of Leronlimab (PRO 140) which Demonstrated Superior Efficacy and Safety in Heavily Treatment-Experienced HIV Patients

VANCOUVER, Washington, Apr 04, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that […]